

News Release

First Ameluz[®] sales in Central Eastern European region

Leverkusen, 6 August 2014 – Biofrontera (AIM/FSE:B8F), the European biopharmaceutical company, has started selling its prescription drug Ameluz[®] for the treatment of actinic keratosis in Slovenia, representing the first Ameluz[®] sales in a Central Eastern European country. Biofrontera Pharma GmbH is the official distributor in Slovenia, working in conjunction with its local partner PHA FARMED d.o.o., Ljubljana. The PDT treatment and Ameluz[®] are fully reimbursed by the public health care system in Slovenia.

Four clinics have now introduced PDT with Biofrontera's PDT lamp BF-RhodoLED[®] and had first Ameluz[®] prescriptions, already an excellent coverage for a small country such as Slovenia. Ameluz[®] PDT is now available at the

- Derma Centre Maribor.
- University Clinical Centre in Ljubljana University Dermatovenerological Clinic.
- University Medical Centre in Maribor, Department of Dermatology and Venereal Diseases.
- General Hospital in Celje, Department of Dermatovenerology.

Dermatologist Dr. Sandi Luft, founder of the Derma Centre Maribor, is the first who started using PDT with BF-RhodoLED[®] and Ameluz[®] in Slovenia:

"At first, I always prioritize patient and the treatment results. If the efficiency of the treatment is satisfying, I am very confident to recommend the therapy to my professional colleges and other patients. Actinic keratosis is a common skin disease, which is recently successfully treated by PDT. Derma Centre Maribor has just implemented PDT with BF-RhodoLED[®] and the medicine Ameluz[®]. The results show that no more than two visits of patients are needed to achieve almost complete clearance, which is not common with other available treatments of actinic keratosis. I can only confirm that my patients are very satisfied also with the excellent cosmetic result."

Slavica Čamer, CEO of the local representative PHA FARMED, commented: "All the healthcare stakeholders in Slovenia have agreed on the value of PDT with Ameluz[®]. The national regulators and insurance companies have recognised the fact that this treatment option is, due to its unmatched clearance rates, saving money for the health care system in the long run, and have made full reimbursement possible. Consequently, patients in Slovenia have now the possibility to be treated with the most efficient treatment option available for the indication."

News Release

Enquiries

Biofrontera AG	+49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer	press@biofrontera.com
Thomas Schaffer , Chief Financial Officer	www.biofrontera.com
Anke zur Mühlen, Corporate Communications	
Brainwell Asset Solutions	+49 (0) 152 08931514
Jürgen Benker	
finnCap (Nomad and Broker)	+44(0) 20 7220 0500
Geoff Nash / Christopher Raggett (Corporate Finance)	
Steven Norcross(Corporate Broking)	
Seton Services Limited (IR)	+44 (0) 20 7603 6797
Toni Vallen	
Gable Communications	+44 (0) 20 7193 7463
Justine James / John Bick	+44 (0) 7872 061007

Notes to Editors:

Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is **Ameluz**[®], a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz[®] for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.

In addition, the Company markets the **Belixos**[®] cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.

Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.

www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.